CAR-T Targeting Nectin4/FAP / Zhejiang Qixin Biotech - LARVOL DELTA

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment (Front Immunol) - "The second one, cited earlier, is a phase I clinical trial (NCT03932565) using fourth-generation CAR-T cells coproducing IL-7 and CCL19/IL-2 in patients with Nectin4-positive advanced malignant solid tumors such as NSCLC, breast, bladder, pancreatic and ovarian cancer. An approach of intravenous infusion combined with intratumoral injection of Nectin4/FAP-targeted CAR-T cells will be undertaken. The clinical trial is ongoing and still recruiting..."

Trial status • Oncology • Solid Tumor